Skip to main content
SpringerLink
Log in

Pathologic Aspects of Hepatocellular Tumors

  • Chapter
  • First Online:
Hepatocellular Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

  • 1465 Accesses

Abstract

Hepatocellular tumors are pathologically divided into a limited number of entities such as focal nodular hyperplasia, hepatocellular adenoma, hepatocellular carcinoma and its variants, and hepatoblastoma. Recent advances in immunophenotypic and molecular characterization have led to an increased appreciation of the complexities of these growths. For example, subtypes of hepatocellular adenomas with differing premalignant potentials have been defined, our ability to differentiate hepatocellular carcinoma from high-grade dysplasia continues to improve, and molecular similarities of histologically discordant elements of combined hepatocellular/cholangiocellular carcinoma have been reported. This chapter describes pathologic, immunophenotypic, and molecular features of hepatocellular tumors. Continued progress in our understanding of these growths at the cellular and subcellular levels suggests that categorization of these tumors may continue to evolve as additional significant clinicopathologic correlates are discovered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46:521–527.

    PubMed  CAS  Google Scholar 

  2. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48:163–170.

    PubMed  CAS  Google Scholar 

  3. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–524.

    PubMed  CAS  Google Scholar 

  4. Bjerring PN, Jacobsen O, Biagini M, Skjoldbye B, Horn T. [Focal nodular hyperplasia]. Ugeskr Laeger. 2007;169:410–414.

    Google Scholar 

  5. Sato A, Rai T, Takahashi A, et al. A case of rapidly expanding and increasing focal nodular hyperplasia. Fukushima J Med Sci. 2006;52:149–155.

    PubMed  Google Scholar 

  6. Buscarini E, Danesino C, Plauchu H, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol. 2004;30:1089–1097.

    PubMed  Google Scholar 

  7. Joyner BL, Jr., Levin TL, Goyal RK, Newman B. Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatr Radiol. 2005;35:1234–1239.

    PubMed  Google Scholar 

  8. Rahili A, Cai J, Trastour C, et al. Spontaneous rupture and hemorrhage of hepatic focal nodular hyperplasia in lobus caudatus. J Hepatobiliary Pancreat Surg. 2005;12:138–142.

    PubMed  Google Scholar 

  9. Petsas T, Tsamandas A, Tsota I, et al. A case of hepatocellular carcinoma arising within large focal nodular hyperplasia with review of the literature. World J Gastroenterol. 2006;12:6567–6571.

    PubMed  Google Scholar 

  10. Yamamoto M, Ariizumi S, Yoshitoshi K, Saito A, Nakano M, Takasaki K. Hepatocellular carcinoma with a central scar and a scalloped tumor margin resembling focal nodular hyperplasia in macroscopic appearance. J Surg Oncol. 2006;94:587–591.

    PubMed  Google Scholar 

  11. Shen YH, Fan J, Wu ZQ, et al. Focal nodular hyperplasia of the liver in 86 patients. Hepatobiliary Pancreat Dis Int. 2007;6:52–57.

    PubMed  Google Scholar 

  12. Imkie M, Myers SA, Li Y, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. 2005;50:633–637.

    PubMed  Google Scholar 

  13. Sotiropoulos GC, Bockhorn M, Molmenti EP, Fouzas I, Broelsch CE, Lang H. Hepatocellular carcinoma as a coincidental finding in a patient undergoing surgery for focal nodular hyperplasia. Liver Int. 2008;28:578–579.

    PubMed  Google Scholar 

  14. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979;242:644–648.

    PubMed  CAS  Google Scholar 

  15. Espat J, Chamberlain RS, Sklar C, Blumgart LH. Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner’s syndrome. Dig Surg. 2000;17:640–643.

    PubMed  CAS  Google Scholar 

  16. Lautz TB, Finegold MJ, Chin AC, Superina RA. Giant hepatic adenoma with a typical features in a patient on oxcarbazepine therapy. J Pediatr Surg. 2008;43:751–754.

    PubMed  CAS  Google Scholar 

  17. Lizardi-Cervera J, Cuellar-Gamboa L, Motola-Kuba D. Focal nodular hyperplasia and hepatic adenoma: a review. Ann Hepatol. 2006;5:206–211.

    PubMed  Google Scholar 

  18. Toso C, Majno P, Andres A, et al. Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. World J Gastroenterol. 2005;11:5691–5695.

    PubMed  Google Scholar 

  19. Erdogan D, Busch OR, van Delden OM, Ten Kate FJ, Gouma DJ, van Gulik TM. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int. 2006;26:433–438.

    PubMed  Google Scholar 

  20. van der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg. 2006;93:1495–1502.

    PubMed  Google Scholar 

  21. Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol. 2001;33:234–236.

    PubMed  CAS  Google Scholar 

  22. Chevallier P, Peten EP, Baldini E, Gugenheim J. Pedunculated hepatic adenoma: sonographic and MR imaging features. AJR Am J Roentgenol. 1999;172:1146–1147.

    PubMed  CAS  Google Scholar 

  23. Balci NC, Sirvanci M, Duran C, Akinci A. Hepatic adenomatosis: MRI demonstration with the use of superparamagnetic iron oxide. Clin Imaging. 2002;26:35–38.

    PubMed  Google Scholar 

  24. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21:877–892; discussion 892–874.

    PubMed  CAS  Google Scholar 

  25. Iijima H, Moriwaki Y, Yamamoto T, Takahashi S, Nishigami T, Hada T. Spontaneous regression of hepatic adenoma in a patient with glycogen storage disease type I after hemodialysis: ultrasonographic and CT findings. Intern Med. 2001;40:891–895.

    PubMed  CAS  Google Scholar 

  26. Yoshikawa M, Fukui K, Kuriyama S, et al. Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. J Gastroenterol. 2001;36:52–61.

    PubMed  CAS  Google Scholar 

  27. Vetelainen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int. 2008;28:499–508.

    PubMed  Google Scholar 

  28. Hung CH, Changchien CS, Lu SN, et al. Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging. 2001;26:500–506.

    PubMed  CAS  Google Scholar 

  29. Palmer PE, Christopherson WM, Wolfe HJ. Alpha1-antitrypsin, protein marker in oral contraceptive-associated hepatic tumors. Am J Clin Pathol. 1977;68:736–739.

    PubMed  CAS  Google Scholar 

  30. Poe R, Snover DC. Adenomas in glycogen storage disease type 1. Two cases with unusual histologic features. Am J Surg Pathol. 1988;12:477–483.

    PubMed  CAS  Google Scholar 

  31. Heffelfinger S, Irani DR, Finegold MJ. “Alcoholic hepatitis” in a hepatic adenoma. Hum Pathol. 1987;18:751–754.

    PubMed  CAS  Google Scholar 

  32. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer. 1991;68:341–347.

    PubMed  CAS  Google Scholar 

  33. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol. 2008;21:491–497.

    PubMed  CAS  Google Scholar 

  34. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740–748.

    PubMed  CAS  Google Scholar 

  35. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol. 2008;32:433–444.

    PubMed  Google Scholar 

  36. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–1018.

    PubMed  CAS  Google Scholar 

  37. Cohen C, Lawson D, DeRose PB. Sex and androgenic steroid receptor expression in hepatic adenomas. Hum Pathol. 1998;29:1428–1432.

    PubMed  CAS  Google Scholar 

  38. Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15:189–196.

    PubMed  Google Scholar 

  39. Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol. 2001;25:1388–1396.

    PubMed  CAS  Google Scholar 

  40. Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg. 2001;67:173–178.

    PubMed  CAS  Google Scholar 

  41. Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet. 1991;173:426–431.

    PubMed  CAS  Google Scholar 

  42. Herman P, Pugliese V, Machado MA, et al. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg. 2000;24:372–376.

    PubMed  CAS  Google Scholar 

  43. Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg. 2001;136:1033–1038.

    PubMed  CAS  Google Scholar 

  44. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725–734.

    PubMed  Google Scholar 

  45. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758–1767.

    PubMed  CAS  Google Scholar 

  46. Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer. 1993;72:1557–1563.

    PubMed  CAS  Google Scholar 

  47. Eggel H. Uber das primare carcinom der leber. Beitr Pathol Anat. 1901;30:506.

    Google Scholar 

  48. Shimada M, Rikimaru T, Hamatsu T, et al. The role of macroscopic classification in nodular-type hepatocellular carcinoma. Am J Surg. 2001;182:177–182.

    PubMed  CAS  Google Scholar 

  49. Stroffolini T, Andreone P, Andriulli A, et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology. 1999;56:189–192.

    PubMed  CAS  Google Scholar 

  50. Horie Y, Katoh S, Yoshida H, Imaoka T, Suou T, Hirayama C. Pedunculated hepatocellular carcinoma. Report of three cases and review of literature. Cancer. 1983;51:746–751.

    Google Scholar 

  51. Horie Y, Shigoku A, Tanaka H, et al. Prognosis for pedunculated hepatocellular carcinoma. Oncology. 1999;57:23–28.

    PubMed  CAS  Google Scholar 

  52. Nakashima O, Sugihara S, Eguchi A, Taguchi J, Watanabe J, Kojiro M. Pathomorphologic study of pale bodies in hepatocellular carcinoma. Acta Pathol Jpn. 1992;42:414–418.

    PubMed  CAS  Google Scholar 

  53. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225–237.

    PubMed  CAS  Google Scholar 

  54. Kojiro M. Pathology of early hepatocellular carcinoma: progression from early to advanced. Hepatogastroenterology. 1998;45 Suppl 3:1203–1205.

    PubMed  Google Scholar 

  55. Kanai T, Hirohashi S, Upton MP, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer. 1987;60:810–819.

    PubMed  CAS  Google Scholar 

  56. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990;66:2174–2179.

    CAS  Google Scholar 

  57. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967;67:337–348.

    PubMed  CAS  Google Scholar 

  58. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who under went hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91:1479–1486.

    PubMed  CAS  Google Scholar 

  59. Ohkubo T, Yamamoto J, Sugawara Y, et al. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg. 2000;191:657–660.

    PubMed  CAS  Google Scholar 

  60. Kojiro M, Kawabata K, Kawano Y, Shirai F, Takemoto N, Nakashima T. Hepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 cases. Cancer. 1982;49:2144–2147.

    PubMed  CAS  Google Scholar 

  61. Kojiro M, Nakahara H, Sugihara S, Murakami T, Nakashima T, Kawasaki H. Hepatocellular carcinoma with intra-atrial tumor growth. A clinicopathologic study of 18 autopsy cases. Arch Pathol Lab Med. 1984;108:989–992.

    CAS  Google Scholar 

  62. Nakashima T, Okuda K, Kojiro M, et al. Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer. 1983;51:863–877.

    PubMed  CAS  Google Scholar 

  63. Tantawi B, Cherqui D, Tran van Nhieu J, Kracht M, Fagniez PL. Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg. 1996;83:1522–1525.

    PubMed  CAS  Google Scholar 

  64. Cancer" AJCo. Liver (Including intrahepatic bile ducts). In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual (ed 6). New York: Springer, 2002;131–138.

    Google Scholar 

  65. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928.

    PubMed  CAS  Google Scholar 

  66. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31:840–845.

    Google Scholar 

  67. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338.

    PubMed  CAS  Google Scholar 

  68. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–1769.

    PubMed  Google Scholar 

  69. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 2000;191:389–394.

    PubMed  CAS  Google Scholar 

  70. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–215.

    PubMed  Google Scholar 

  71. UNOS. MELD/PELD Calculator, 2008.

    Google Scholar 

  72. Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer. 2006;107:141–148.

    PubMed  Google Scholar 

  73. Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101:975–982.

    PubMed  Google Scholar 

  74. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40:124–131.

    PubMed  Google Scholar 

  75. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716.

    PubMed  Google Scholar 

  76. Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:1619–1624.

    PubMed  Google Scholar 

  77. Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352–361.

    PubMed  CAS  Google Scholar 

  78. Seo YS, Kim YJ, Um SH, et al. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1267–1275.

    PubMed  Google Scholar 

  79. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.

    PubMed  CAS  Google Scholar 

  80. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.

    PubMed  CAS  Google Scholar 

  81. Ioannou GN, Perkins JD, Carithers RL, Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342–1351.

    PubMed  Google Scholar 

  82. Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW. Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl. 2008;14:443–450.

    PubMed  Google Scholar 

  83. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl. 2003;9:664–671.

    PubMed  Google Scholar 

  84. Komatsu T, Kondo Y, Yamamoto Y, Isono K. Hepatocellular carcinoma presenting well differentiated, normotrabecular patterns in peripheral or metastatic loci. Analysis of 103 resected cases. Acta Pathol Jpn. 1990;40:887–893.

    PubMed  CAS  Google Scholar 

  85. Kondo Y. Histologic features of hepatocellular carcinoma and allied disorders. Pathol Annu. 1985;20 Pt 2:405–430.

    PubMed  Google Scholar 

  86. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis. 1986;6:259–266.

    PubMed  CAS  Google Scholar 

  87. Kondo Y, Nakajima T. Pseudoglandular hepatocellular carcinoma. A morphogenetic study. Cancer. 1987;60:1032–1037.

    PubMed  CAS  Google Scholar 

  88. Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2002;26:25–34.

    PubMed  Google Scholar 

  89. Moon WS, Yu HC, Chung MJ, Kang MJ, Lee DG. Pale bodies in hepatocellular carcinoma. J Korean Med Sci. 2000;15:516–520.

    PubMed  CAS  Google Scholar 

  90. Nakanuma Y, Kono N, Ohta G, et al. Pale eosinophilic inclusions simulating ground-glass appearance of cells of hepatocellular carcinoma. Acta Pathol Jpn. 1982;32:71–81.

    PubMed  CAS  Google Scholar 

  91. Stromeyer FW, Ishak KG, Gerber MA, Mathew T. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. 1980;74:254–258.

    PubMed  CAS  Google Scholar 

  92. Stumptner C, Heid H, Fuchsbichler A, et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Am J Pathol. 1999;154:1701–1710.

    PubMed  CAS  Google Scholar 

  93. Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). Hepatology. 1994;20:1061–1077.

    PubMed  CAS  Google Scholar 

  94. Dominguez-Malagon H, Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol. 2001;25:497–516.

    PubMed  CAS  Google Scholar 

  95. Liu K, He X, Lei XZ, et al. Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol. 2003;9:1946–1949.

    PubMed  Google Scholar 

  96. Tsujimoto T, Kuriyama S, Yamazaki M, et al. Augmented hepatocellular carcinoma progression and depressed Kupffer cell activity in rat cirrhotic livers. Int J Oncol. 2001;18:41–47.

    PubMed  CAS  Google Scholar 

  97. Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438:574–580.

    PubMed  CAS  Google Scholar 

  98. Okuda K, Musha H, Nakajima Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer. 1977;40:1240–1245.

    PubMed  CAS  Google Scholar 

  99. Torimura T, Ueno T, Inuzuka S, Tanaka M, Abe H, Tanikawa K. Mechanism of fibrous capsule formation surrounding hepatocellular carcinoma. Immunohistochemical study. Arch Pathol Lab Med. 1991;115:365–371.

    PubMed  CAS  Google Scholar 

  100. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.

    PubMed  CAS  Google Scholar 

  101. Oriyama T, Yamanaka N, Fujimoto J, Ichikawa N, Okamoto E. Progression of hepatocellular carcinoma as reflected by nuclear DNA ploidy and cellular differentiation. J Hepatol. 1998;28:142–149.

    PubMed  CAS  Google Scholar 

  102. Rua S, Comino A, Fruttero A, et al. Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor. Cancer. 1996;78:1195–1202.

    PubMed  CAS  Google Scholar 

  103. Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91:1154–1158.

    PubMed  CAS  Google Scholar 

  104. Goodman ZD, Terracciano L. Tumours and tumour-like lesions of the liver. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween’s Pathology of the Liver: Churchill Livingstone Elsevier, 2007;761–814.

    Google Scholar 

  105. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol. 2007;42:962–968.

    PubMed  CAS  Google Scholar 

  106. Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol. 2002;17:772–778.

    PubMed  CAS  Google Scholar 

  107. Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest. 2008;88:78–88.

    PubMed  CAS  Google Scholar 

  108. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137–144.

    PubMed  Google Scholar 

  109. Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol. 2004;122:721–727.

    PubMed  CAS  Google Scholar 

  110. Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686–692.

    PubMed  CAS  Google Scholar 

  111. Geramizadeh B, Boub R, Rahsaz M. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Indian J Pathol Microbiol. 2007;50:507–510.

    PubMed  Google Scholar 

  112. Gokden M, Shinde A. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. Diagn Cytopathol. 2005;33:166–172.

    PubMed  Google Scholar 

  113. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol. 2004;11:239–249.

    PubMed  CAS  Google Scholar 

  114. Song HH, Filmus J. The role of glypicans in mammalian development. Biochim Biophys Acta. 2002;1573:241–246.

    PubMed  CAS  Google Scholar 

  115. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012–1024.

    PubMed  CAS  Google Scholar 

  116. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899–906.

    PubMed  Google Scholar 

  117. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612–6621.

    PubMed  CAS  Google Scholar 

  118. Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209–212.

    PubMed  CAS  Google Scholar 

  119. Tien LT, Ito M, Nakao M, et al. Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol. 2005;11:2398–2401.

    PubMed  CAS  Google Scholar 

  120. Miskad UA, Yano Y, Nakaji M, et al. Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia. Pathol Int. 2001;51:916–922.

    PubMed  CAS  Google Scholar 

  121. Ajisaka H, Shimizu K, Miwa K. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma. J Surg Oncol. 2003;84:89–93.

    PubMed  CAS  Google Scholar 

  122. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002;52:19–24.

    PubMed  CAS  Google Scholar 

  123. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–127.

    PubMed  CAS  Google Scholar 

  124. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051–2059.

    PubMed  CAS  Google Scholar 

  125. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709–717.

    PubMed  CAS  Google Scholar 

  126. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res. 2008.

    Google Scholar 

  127. Chau GY, Lee AF, Tsay SH, et al. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology. 2007;51:204–218.

    PubMed  Google Scholar 

  128. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–1218.

    PubMed  CAS  Google Scholar 

  129. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451–1461.

    PubMed  CAS  Google Scholar 

  130. Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95:611–619.

    PubMed  CAS  Google Scholar 

  131. Sera T, Hiasa Y, Mashiba T, et al. Wilms’ tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer. 2008;44:600–608.

    PubMed  CAS  Google Scholar 

  132. Rikimaru T, Taketomi A, Yamashita Y, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007;72:69–74.

    PubMed  CAS  Google Scholar 

  133. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008;48:83–90.

    PubMed  CAS  Google Scholar 

  134. Niu RF, Zhang L, Xi GM, et al. Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2007;26:385–394.

    PubMed  CAS  Google Scholar 

  135. Yi X, Luk JM, Lee NP, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008;7:315–325.

    PubMed  CAS  Google Scholar 

  136. Wang H, Pan K, Zhang HK, et al. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535–541.

    PubMed  CAS  Google Scholar 

  137. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol. 2001;25:1297–1303.

    PubMed  CAS  Google Scholar 

  138. Xiao SY, Wang HL, Hart J, Fleming D, Beard MR. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol. 2001;159:1415–1421.

    PubMed  CAS  Google Scholar 

  139. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171–177.

    PubMed  CAS  Google Scholar 

  140. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 1999;59:5758–5767.

    PubMed  CAS  Google Scholar 

  141. Deprez C, Vangansbeke D, Fastrez R, Pasteels JL, Verhest A, Kiss R. Nuclear DNA content, proliferation index, and nuclear size determination in normal and cirrhotic liver, and in benign and malignant primary and metastatic hepatic tumors. Am J Clin Pathol. 1993;99:558–565.

    PubMed  CAS  Google Scholar 

  142. Erler BS, Hsu L, Truong HM, et al. Image analysis and diagnostic classification of hepatocellular carcinoma using neural networks and multivariate discriminant functions. Lab Invest. 1994;71:446–451.

    PubMed  CAS  Google Scholar 

  143. Vertemati M, Vizzotto L, Moscheni C, Dhillon A, Quaglia A. A morphometric model to minimize subjectivity in the histological assessment of hepatocellular carcinoma and its precursors in cirrhosis. Microsc Res Tech. 2008;71:606–613.

    PubMed  Google Scholar 

  144. Suzuki K, Hirooka Y, Tsujitani S, Yamane Y, Ikeguchi M, Kaibara N. Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma. Anticancer Res. 2000;20:1257–1262.

    PubMed  CAS  Google Scholar 

  145. Tannapfel A, Geissler F, Kockerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol. 1999;187:439–445.

    PubMed  CAS  Google Scholar 

  146. Suehiro T, Matsumata T, Itasaka H, Yamamoto K, Kawahara N, Sugimachi K. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen. Cancer. 1995;76:399–405.

    PubMed  CAS  Google Scholar 

  147. Chao Y, Shih YL, Chiu JH, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 1998;58:985–990.

    PubMed  CAS  Google Scholar 

  148. Tannapfel A, Anhalt K, Hausermann P, et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 2003;201:238–249.

    PubMed  CAS  Google Scholar 

  149. Peng SY, Chou SP, Hsu HC. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol. 1998;29:281–289.

    PubMed  CAS  Google Scholar 

  150. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667–676.

    PubMed  CAS  Google Scholar 

  151. Garcia EJ, Lawson D, Cotsonis G, Cohen C. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol. 2002;10:210–217.

    PubMed  CAS  Google Scholar 

  152. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378–1385.

    PubMed  CAS  Google Scholar 

  153. Nagao K, Tomimatsu M, Endo H, Hisatomi H, Hikiji K. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol. 1999;34:83–87.

    PubMed  CAS  Google Scholar 

  154. Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol. 1998;69:119–124.

    PubMed  CAS  Google Scholar 

  155. Kobayashi T, Kubota K, Takayama T, Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001;181:284–288.

    PubMed  CAS  Google Scholar 

  156. Azechi H, Nishida N, Fukuda Y, et al. Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology. 2001;60:346–354.

    PubMed  CAS  Google Scholar 

  157. Cohen C, DeRose PB. Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. Mod Pathol. 1994;7:536–539.

    PubMed  CAS  Google Scholar 

  158. Cui X, Hui AM, Li X, et al. Alterations of retinoblastoma protein and p16INK4 protein expression in extrahepatic bile duct carcinomas. Hepatogastroenterology. 2000;47:1216–1220.

    PubMed  CAS  Google Scholar 

  159. Hui AM, Li X, Makuuchi M, Takayama T, Kubota K. Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer. 1999;84:604–608.

    PubMed  CAS  Google Scholar 

  160. Hui AM, Shi YZ, Li X, Takayama T, Makuuchi M. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett. 2000;154:93–99.

    PubMed  CAS  Google Scholar 

  161. Huo TI, Wang XW, Forgues M, et al. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene. 2001;20:3620–3628.

    PubMed  CAS  Google Scholar 

  162. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res. 1998;18:555–564.

    PubMed  CAS  Google Scholar 

  163. Peng XM, Peng WW, Yao JL. Codon 249 mutations of p53 gene in development of hepatocellular carcinoma. World J Gastroenterol. 1998;4:125–127.

    PubMed  CAS  Google Scholar 

  164. Sheen-Chen SM, Chen WJ, Eng HL, Sheen CC, Chou FF, Cheng YF. Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest. 1999;17:581–585.

    PubMed  CAS  Google Scholar 

  165. Shiota G, Kishimoto Y, Suyama A, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol. 1997;27:661–668.

    PubMed  CAS  Google Scholar 

  166. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979–992.

    PubMed  CAS  Google Scholar 

  167. Prange W, Breuhahn K, Fischer F, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol. 2003;201:250–259.

    PubMed  CAS  Google Scholar 

  168. Torbenson M, Kannangai R, Abraham S, Sahin F, Choti M, Wang J. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma. Am J Clin Pathol. 2004;122:377–382.

    PubMed  CAS  Google Scholar 

  169. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res. 2000;6:3516–3521.

    PubMed  CAS  Google Scholar 

  170. Zeng WJ, Liu GY, Xu J, Zhou XD, Zhang YE, Zhang N. Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma. World J Gastroenterol. 2002;8:1040–1044.

    PubMed  CAS  Google Scholar 

  171. Chiappini F, Gross-Goupil M, Saffroy R, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis. 2004;25:541–547.

    PubMed  CAS  Google Scholar 

  172. Wilkens L, Bredt M, Flemming P, Klempnauer J, Heinrich Kreipe H. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol. 2000;192:43–51.

    PubMed  CAS  Google Scholar 

  173. Iizuka N, Tamesa T, Sakamoto K, Miyamoto T, Hamamoto Y, Oka M. Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma. Oncol Rep. 2006;16:1137–1142.

    PubMed  CAS  Google Scholar 

  174. Ho MC, Lin JJ, Chen CN, et al. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol. 2006;13:1474–1484.

    PubMed  Google Scholar 

  175. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582–1595.

    PubMed  CAS  Google Scholar 

  176. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–416.

    PubMed  CAS  Google Scholar 

  177. Mas VR, Fisher RA, Archer KJ, et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation. 2007;83:973–981.

    PubMed  Google Scholar 

  178. Iizuka N, Hamamoto Y, Tsunedomi R, Oka M. Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci. 2008;99:659–665.

    PubMed  CAS  Google Scholar 

  179. Chen GG, Ho RL, Wong J, Lee KF, Lai PB. Single nucleotide polymorphism in the promoter region of human alpha-fetoprotein (AFP) gene and its significance in hepatocellular carcinoma (HCC). Eur J Surg Oncol. 2007;33:882–886.

    PubMed  CAS  Google Scholar 

  180. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007;14:217–223.

    Google Scholar 

  181. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma – an a typical variant with a favorable prognosis. Cancer. 1980;46:1448–1455.

    PubMed  CAS  Google Scholar 

  182. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803.

    PubMed  Google Scholar 

  183. Hoshino H, Katada N, Nishimura D, et al. Case report: fibrolamellar hepatocellular carcinoma in a Japanese woman: a case report and review of Japanese cases. J Gastroenterol Hepatol. 1996;11:551–555.

    Google Scholar 

  184. Yoshimi F, Asato Y, Amemiya R, Itabashi M, Nakamura K. Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case. Surg Today. 2002;32:174–179.

    PubMed  Google Scholar 

  185. Mansouri D, Van Nhieu JT, Couanet D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. 2006;34:568–571.

    PubMed  Google Scholar 

  186. Bilbao I, Vilallonga R, Allende E, et al. [Krukenberg’s tumor as the first clinical manifestation of fibrolamellar hepatocarcinoma]. Gastroenterol Hepatol. 2008;31:341–346.

    PubMed  Google Scholar 

  187. Ichikawa T, Federle MP, Grazioli L, Marsh W. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology. 2000;217:145–151.

    PubMed  CAS  Google Scholar 

  188. Yamaguchi R, Tajika T, Kanda H, Nakanishi K, Kawanishi J. Fibrolamellar carcinoma of the liver. Hepatogastroenterology. 1999;46:1706–1709.

    PubMed  CAS  Google Scholar 

  189. Saul SH, Titelbaum DS, Gansler TS, et al. The fibrolamellar variant of hepatocellular carcinoma. Its association with focal nodular hyperplasia. Cancer. 1987;60:3049–3055.

    PubMed  CAS  Google Scholar 

  190. Caballero T, Aneiros J, Lopez-Caballero J, Gomez-Morales M, Nogales F. Fibrolamellar hepatocellular carcinoma. An immunohistochemical and ultrastructural study. Histopathology. 1985;9:445–456.

    PubMed  CAS  Google Scholar 

  191. An T, Ghatak N, Kastner R, Kay S, Lee HM. Hyaline globules and intracellular lumina in a hepatocellular carcinoma. Am J Clin Pathol. 1983;79:392–396.

    PubMed  CAS  Google Scholar 

  192. Lefkowitch JH, Muschel R, Price JB, Marboe C, Braunhut S. Copper and copper-binding protein in fibrolamellar liver cell carcinoma. Cancer. 1983;51:97–100.

    PubMed  CAS  Google Scholar 

  193. Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol. 2005;58:884–887.

    PubMed  CAS  Google Scholar 

  194. Seitz G, Zimmermann A, Friess H, Buchler MW. Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol. 2002;33:765–769.

    PubMed  Google Scholar 

  195. Cheuk W, Chan JK. Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med. 2001;125:1235–1238.

    PubMed  CAS  Google Scholar 

  196. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005;124:512–518.

    PubMed  Google Scholar 

  197. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143:1050–1054.

    PubMed  CAS  Google Scholar 

  198. Van Eyken P, Sciot R, Brock P, Casteels-Van Daele M, Ramaekers FC, Desmet VJ. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology. 1990;17:101–107.

    PubMed  Google Scholar 

  199. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19:784–794.

    PubMed  CAS  Google Scholar 

  200. Okano A, Hajiro K, Takakuwa H, Kobashi Y. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. 1998;93:1144–1145.

    PubMed  CAS  Google Scholar 

  201. Nerlich AG, Majewski S, Hunzelmann N, et al. Excessive collagen formation in fibrolamellar carcinoma of the liver: a morphological and biochemical study. Mod Pathol. 1992;5:580–585.

    PubMed  CAS  Google Scholar 

  202. Orsatti G, Hytiroglou P, Thung SN, Ishak KG, Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17:152–156.

    PubMed  CAS  Google Scholar 

  203. Wilkens L, Bredt M, Flemming P, Kubicka S, Klempnauer J, Kreipe H. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol. 2000;114:867–874.

    PubMed  CAS  Google Scholar 

  204. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica. 2003;95:71–82.

    PubMed  CAS  Google Scholar 

  205. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer. 1998;77:776–782.

    PubMed  CAS  Google Scholar 

  206. Terris B, Pineau P, Bregeaud L, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene. 1999;18:6583–6588.

    PubMed  CAS  Google Scholar 

  207. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer. 2005;35:53–60.

    PubMed  CAS  Google Scholar 

  208. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. 2008;21:670–675.

    PubMed  CAS  Google Scholar 

  209. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120:3163–3172.

    PubMed  CAS  Google Scholar 

  210. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. 2007;38:639–644.

    PubMed  CAS  Google Scholar 

  211. Hemming AW, Langer B, Sheiner P, Greig PD, Taylor BR. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1:342–346.

    PubMed  CAS  Google Scholar 

  212. Zografos GN, Palmer S, Papastratis G, Habib NA. Aggressive surgical management of fibrolamellar hepatocellular carcinoma in puberty. Eur J Surg Oncol. 1997;23:570–572.

    PubMed  CAS  Google Scholar 

  213. Starzl TE, Iwatsuki S, Shaw BW, Jr., Nalesnik MA, Farhi DC, Van Thiel DH. Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet. 1986;162:145–148.

    PubMed  CAS  Google Scholar 

  214. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26:877–883.

    PubMed  CAS  Google Scholar 

  215. Moreno-Luna LE, Arrieta O, Garcia-Leiva J, et al. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005;5:142.

    PubMed  Google Scholar 

  216. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–1338.

    PubMed  Google Scholar 

  217. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97:2006–2012.

    PubMed  Google Scholar 

  218. Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol. 2001;33:195–200.

    PubMed  CAS  Google Scholar 

  219. Wu PC, Lai CL, Lam KC, Lok AS, Lin HJ. Clear cell carcinoma of liver. An ultrastructural study. Cancer. 1983;52:504–507.

    PubMed  CAS  Google Scholar 

  220. Takahashi A, Saito H, Kanno Y, et al. Case of clear-cell hepatocellular carcinoma that developed in the normal liver of a middle-aged woman. World J Gastroenterol. 2008;14:129–131.

    PubMed  Google Scholar 

  221. Liu Z, Ma W, Li H, Li Q. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008;38:291–299.

    PubMed  Google Scholar 

  222. Sasaki K, Okuda S, Takahashi M, Sasaki M. Hepatic clear cell carcinoma associated with hypoglycemia and hypercholesterolemia. Cancer. 1981;47:820–822.

    PubMed  CAS  Google Scholar 

  223. Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, Reynes M. Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 2001;38:225–231.

    PubMed  CAS  Google Scholar 

  224. Orsatti G, Arnold MM, Paronetto F. DNA image cytometric analysis of primary clear cell carcinoma of the liver. Arch Pathol Lab Med. 1994;118:1226–1229.

    PubMed  CAS  Google Scholar 

  225. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874–881.

    PubMed  CAS  Google Scholar 

  226. Lao XM, Zhang YQ, Jin X, et al. Primary clear cell carcinoma of liver – clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology. 2006;53:128–132.

    PubMed  Google Scholar 

  227. Jeon SW, Lee MK, Lee YD, et al. Clear cell hepatocellular carcinoma with spontaneous regression of primary and metastatic lesions. Korean J Intern Med. 2005;20:268–273.

    PubMed  Google Scholar 

  228. Okuda K. Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol. 1997;12:S314–318.

    PubMed  CAS  Google Scholar 

  229. Albar JP, De Miguel F, Esbrit P, Miranda R, Fernandez-Flores A, Sarasa JL. Immunohistochemical detection of parathyroid hormone-related protein in a rare variant of hepatic neoplasm (sclerosing hepatic carcinoma). Hum Pathol. 1996;27:728–731.

    PubMed  CAS  Google Scholar 

  230. Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: Comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol. 2007.

    Google Scholar 

  231. Fujii T, Zen Y, Nakanuma Y. Minute scirrhous hepatocellular carcinomas undergoing different carcinogenetic processes. Pathol Int. 2007;57:443–448.

    PubMed  Google Scholar 

  232. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1470–1477.

    PubMed  Google Scholar 

  233. Matsuura S, Aishima S, Taguchi K, et al. “Scirrhous” type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382–390.

    PubMed  CAS  Google Scholar 

  234. Sugiki T, Yamamoto M, Aruga A, Takasaki K, Nakano M. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1. J Surg Oncol. 2004;88:104–107.

    PubMed  Google Scholar 

  235. Okamura N, Yoshida M, Shibuya A, Sugiura H, Okayasu I, Ohbu M. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int. 2005;55:724–731.

    PubMed  CAS  Google Scholar 

  236. Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008.

    Google Scholar 

  237. Hong CK, Yang JM, Kang BK, et al. A case of combined hepatocellular-cholangiocarcinoma with underlying schistosomiasis. Korean J Intern Med. 2007;22:283–286.

    PubMed  Google Scholar 

  238. Inaba K, Suzuki S, Sakaguchi T, et al. Double primary liver cancer (intrahepatic cholangiocarcinoma and hepatocellular carcinoma) in a patient with hepatitis C virus-related cirrhosis. J Hepatobiliary Pancreat Surg. 2007;14:204–209.

    PubMed  Google Scholar 

  239. Ishikawa K, Sasaki A, Haraguchi N, Yoshikawa Y, Mori M. A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist. 2007;12:320–324.

    PubMed  CAS  Google Scholar 

  240. Tang D, Nagano H, Nakamura M, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg. 2006;10:987–998.

    PubMed  Google Scholar 

  241. Papotti M, Sambataro D, Marchesa P, Negro F. A combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features. Liver. 1997;17:47–52.

    PubMed  CAS  Google Scholar 

  242. Wakasa T, Wakasa K, Shutou T, et al. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology. 2007;54:508–513.

    PubMed  Google Scholar 

  243. Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol. 2007;31:783–791.

    PubMed  Google Scholar 

  244. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S. Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai. 2007;90:574–580.

    Google Scholar 

  245. Zhang F, Chen XP, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008;52:224–232.

    PubMed  CAS  Google Scholar 

  246. Imai Y, Oda H, Arai M, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996;87:1056–1062.

    PubMed  CAS  Google Scholar 

  247. Yano H, Iemura A, Haramaki M, et al. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol. 1996;24:413–422.

    PubMed  CAS  Google Scholar 

  248. Gil-Benso R, Martinez-Lorente A, Pellin-Perez A, et al. Characterization of a new rat cell line established from 2'AAF-induced combined hepatocellular cholangiocellular carcinoma. In Vitro Cell Dev Biol Anim. 2001;37:17–25.

    PubMed  CAS  Google Scholar 

  249. Fu Y, Kobayashi S, Kushida Y, et al. Sarcomatoid hepatocellular carcinoma with chondroid variant: case report with immunohistochemical findings. Pathol Int. 2000;50:919–922.

    PubMed  CAS  Google Scholar 

  250. Akasofu M, Kawahara E, Kaji K, Nakanishi I. Sarcomatoid hepatocellular-carcinoma showing rhabdomyoblastic differentiation in the adult cirrhotic liver. Virchows Arch. 1999;434:511–515.

    PubMed  CAS  Google Scholar 

  251. Sasaki A, Yokoyama S, Nakayama I, Nakashima K, Kim YI, Kitano S. Sarcomatoid hepatocellular carcinoma with osteoclast-like giant cells: case report and immunohistochemical observations. Pathol Int. 1997;47:318–324.

    PubMed  CAS  Google Scholar 

  252. Cho MS, Lee SN, Sung SH, Han WS. Sarcomatoid hepatocellular carcinoma with hepatoblastoma-like features in an adult. Pathol Int. 2004;54:446–450.

    PubMed  Google Scholar 

  253. Haratake J, Horie A. An immunohistochemical study of sarcomatoid liver carcinomas. Cancer. 1991;68:93–97.

    PubMed  CAS  Google Scholar 

  254. Park YN, Kim KR, Park HS et al. Expression of the serum response factor in hepatocellular carcinoma: implications for piethelial-mesenchymal transition. Int J Oncol 2007;31:1309–1315.

    PubMed  CAS  Google Scholar 

  255. Barron MR, Belaguli NS, Zhang SX, et al. Serum response factor, an enriched cardiac mesoderm obligatory factor, is a downstream gene target for Tbx genes. J Biol Chem. 2005;280:11816–11828.

    PubMed  CAS  Google Scholar 

  256. Catanzarite V, Hilfiker M, Daneshmand S, Willert J. Prenatal diagnosis of fetal hepatoblastoma: case report and review of the literature. J Ultrasound Med. 2008;27:1095–1098.

    Google Scholar 

  257. Altmann HW. Epithelial and mixed hepatoblastoma in the adult. Histological observations and general considerations. Pathol Res Pract. 1992;188:16–26.

    PubMed  CAS  Google Scholar 

  258. Bortolasi L, Marchiori L, Dal Dosso I, Colombari R, Nicoli N. Hepatoblastoma in adult age: a report of two cases. Hepatogastroenterology. 1996;43:1073–1078.

    PubMed  CAS  Google Scholar 

  259. Remes-Troche JM, Montano-Loza A, Meza-Junco J, Garcia-Leiva J, Torre-Delgadillo A. Hepatoblastoma in adult age. A case report and literature review. Ann Hepatol. 2006;5:179–181.

    Google Scholar 

  260. Yoshida R, Ogata T, Masawa N, Nagai T. Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. Pediatr Blood Cancer. 2008;50:1274–1276.

    PubMed  Google Scholar 

  261. Giardiello FM, Offerhaus GJ, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr. 1991;119:766–768.

    PubMed  CAS  Google Scholar 

  262. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer. 1967;20:396–422.

    PubMed  CAS  Google Scholar 

  263. Ito E, Sato Y, Kawauchi K, et al. Type 1a glycogen storage disease with hepatoblastoma in siblings. Cancer. 1987;59:1776–1780.

    PubMed  CAS  Google Scholar 

  264. Lynch HT, Thorson AG, McComb RD, Franklin BA, Tinley ST, Lynch JF. Familial adenomatous polyposis and extracolonic cancer. Dig Dis Sci. 2001;46:2325–2332.

    PubMed  CAS  Google Scholar 

  265. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol. 1983;14:512–537.

    PubMed  CAS  Google Scholar 

  266. Watanabe I, Yamaguchi M, Kasai M. Histologic characteristics of gonadotropin-producing hepatoblastoma: a survey of seven cases from Japan. J Pediatr Surg. 1987;22:406–411.

    PubMed  CAS  Google Scholar 

  267. Lack EE, Neave C, Vawter GF. Hepatoblastoma. A clinical and pathologic study of 54 cases. Am J Surg Pathol. 1982;6:693–705.

    PubMed  CAS  Google Scholar 

  268. Emura I, Ohnishi Y, Yamashita Y, Iwafuchi M. Immunohistochemical and ultrastructural study on erythropoiesis in hepatoblastoma. Acta Pathol Jpn. 1985;35:79–86.

    PubMed  CAS  Google Scholar 

  269. Gonzalez-Crussi F. Undifferentiated small cell (“anaplastic”) hepatoblastoma. Pediatr Pathol. 1991;11:155–161.

    PubMed  CAS  Google Scholar 

  270. Kasai M, Watanabe I. Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. A study of 70 cases collected in Japan. Cancer. 1970;25:551–563.

    PubMed  CAS  Google Scholar 

  271. Stocker JT. Hepatoblastoma. Semin Diagn Pathol. 1994;11:136–143.

    PubMed  CAS  Google Scholar 

  272. Joshi VV, Kaur P, Ryan B, Saad S, Walters TR. Mucoid anaplastic hepatoblastoma. A case report. Cancer. 1984;54:2035–2039.

    PubMed  CAS  Google Scholar 

  273. Manivel C, Wick MR, Abenoza P, Dehner LP. Teratoid hepatoblastoma. The nosologic dilemma of solid embryonic neoplasms of childhood. Cancer. 1986;57:2168–2174.

    PubMed  CAS  Google Scholar 

  274. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol. 1998;11:934–938.

    PubMed  CAS  Google Scholar 

  275. Zynger DL, Gupta A, Luan C, Chou PM, Yang GY, Yang XJ. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224–230.

    PubMed  CAS  Google Scholar 

  276. Ruck P, Xiao JC, Pietsch T, Von Schweinitz D, Kaiserling E. Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology. 1997;31:324–329.

    PubMed  CAS  Google Scholar 

  277. Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem. 2004;52:1495–1501.

    PubMed  CAS  Google Scholar 

  278. Morinaga S, Yamaguchi M, Watanabe I, Kasai M, Ojima M, Sasano N. An immunohistochemical study of hepatoblastoma producing human chorionic gonadotropin. Cancer. 1983;51:1647–1652.

    PubMed  CAS  Google Scholar 

  279. Ramsay AD, Bates AW, Williams S, Sebire NJ. Variable antigen expression in hepatoblastomas. Appl Immunohistochem Mol Morphol. 2008;16:140–147.

    PubMed  CAS  Google Scholar 

  280. Curia MC, Zuckermann M, De Lellis L, et al. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol. 2008;21:7–14.

    PubMed  CAS  Google Scholar 

  281. Yamaoka H, Ohtsu K, Sueda T, Yokoyama T, Hiyama E. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol Rep. 2006;15:551–556.

    PubMed  CAS  Google Scholar 

  282. Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol. 2005;8:435–447.

    PubMed  CAS  Google Scholar 

  283. Adesina AM, Nguyen Y, Guanaratne P, et al. FOXG1 is overexpressed in hepatoblastoma. Hum Pathol. 2007;38:400–409.

    PubMed  CAS  Google Scholar 

  284. Katoh M. Human FOX gene family (Review). Int J Oncol. 2004;25:1495–1500.

    Google Scholar 

  285. Terrace JD, Currie IS, Hay DC, et al. Progenitor cell characterization and location in the developing human liver. Stem Cells Dev. 2007;16:771–778.

    PubMed  CAS  Google Scholar 

  286. Tanimizu N, Nishikawa M, Saito H, Tsujimura T, Miyajima A. Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci. 2003;116:1775–1786.

    PubMed  CAS  Google Scholar 

  287. Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol. 2006;12:6531–6535.

    PubMed  CAS  Google Scholar 

  288. Austin MT, Leys CM, Feurer ID, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006;41:182–186.

    PubMed  Google Scholar 

  289. D’Antiga L, Vallortigara F, Cillo U, et al. Features predicting unresectability in hepatoblastoma. Cancer. 2007;110:1050–1058.

    PubMed  Google Scholar 

  290. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer. 2008;44:545–550.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Transplantation and Hepatic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Michael A. Nalesnik MD, Tong Wu MD, PhD, Eizaburo Sasatomi MD & Anthony J. Demetris MD

Authors
  1. Michael A. Nalesnik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tong Wu MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eizaburo Sasatomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony J. Demetris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kimmel Cancer Center, Thomas Jefferson University, S. 10th Street 233, Philadelphia, 19107, Pennsylvania, USA

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Nalesnik, M.A., Wu, T., Sasatomi, E., Demetris, A.J. (2009). Pathologic Aspects of Hepatocellular Tumors. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60327-376-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-376-3_6

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-373-2

  • Online ISBN: 978-1-60327-376-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation